Bloodless medicine combines anemia treatment, blood conservation, and individualized planning for patients who decline transfusion. Abib and colleagues review the Johns Hopkins experience and the broader patient blood management literature, emphasizing preparation before surgery and prevention of avoidable blood loss throughout hospitalization. For perfusion teams, the review connects circuit-related hemodilution, autologous techniques, cell salvage, and clear documentation of the patient’s choices.
Important Update on Individual Treatment Choices
Editorial update, November 1, 2026: The source review describes donor red cells, white cells, plasma, and platelets as prohibited for Jehovah’s Witnesses. Current official medical guidance states that, following a September 18, 2026 announcement, acceptance of these donor components is an individual decision; whole-blood transfusion remains prohibited. This differs from the review’s wording. Clinicians should ask each patient directly and document current choices rather than infer consent or refusal from religious identity. The linked source PDF is unchanged.
Bloodless Medicine Begins Before the Operation
The review identifies early diagnosis and treatment of anemia as a foundation of care. The opportunity is greatest when an elective referral allows time to investigate iron deficiency and other causes, select appropriate treatment, and assess the response before expected blood loss.
Oral or intravenous iron, and selected use of erythropoiesis-stimulating agents, are discussed as ways to support red-cell production. These treatments have different indications, response times, and risks. The paper’s institutional order sets and rescue regimens should not be treated as universal prescribing instructions.
The authors also discuss procedure-specific estimates of blood loss and patient blood volume when planning a preoperative hemoglobin goal. A target derived from a small validation cohort is a planning aid rather than proof of a safe hemoglobin level for every operation or patient.
Document Products and Procedures Separately
A useful treatment plan records the patient’s decisions about specific components, fractions, medications, and procedures. Acceptance of cell salvage, acute normovolemic hemodilution (ANH), cardiopulmonary bypass (CPB), albumin, factor concentrates, or stored autologous blood should be discussed directly. Agreement to one does not establish agreement to the others.
The source discusses the March 2026 change allowing individual decisions about collection, storage, and reinfusion of one’s own blood. Preoperative autologous donation nevertheless requires lead time and collection infrastructure, and can itself worsen anemia. It does not replace anemia optimization or establish that donation is clinically appropriate.
For extracorporeal procedures, the plan should capture any patient-specific requirements concerning continuity of the circuit and handling of collected blood. A private, informed discussion and an accessible record of decisions help the operating room and intensive care teams work from the same plan.
Intraoperative Conservation and the Perfusion Role
The review emphasizes meticulous hemostasis, appropriate temperature management, antifibrinolytic therapy, and targeted coagulation assessment. These measures work as a coordinated pathway. They do not remove the need to identify surgical bleeding or account for the patient’s cardiac and end-organ perfusion requirements.
| Approach | Purpose | Planning consideration |
|---|---|---|
| Low-volume circuits and autologous priming | Limit dilution of circulating red cells | Balance dilution reduction with venous return, reservoir volume, and stable perfusion. |
| Cell salvage | Recover and wash shed red cells | Confirm consent, circuit requirements, and procedure-specific contamination concerns. |
| ANH | Preserve autologous whole blood for later reinfusion | Requires appropriate starting red-cell mass, physiological tolerance, and an agreed collection plan. |
| Ultrafiltration | Manage fluid and hemoconcentration during selected cardiac procedures | Use within the overall volume, pressure, and oxygen-delivery strategy. |
| Point-of-care coagulation testing | Identify and address specific hemostatic deficits | Match potential treatments to both the test findings and the patient’s documented choices. |
Cell salvage returns a red-cell-rich product and does not replace all plasma proteins or platelets lost through bleeding. Similarly, minimizing hemodilution is valuable only when accompanied by adequate flow, oxygen delivery, and hemodynamic stability. The article’s discussion of controlled hypotension in selected noncardiac settings should not be interpreted as a universal cardiac surgery or CPB pressure target.
Preventing Postoperative Blood Loss
The review highlights the cumulative cost of diagnostic phlebotomy. Reviewing the necessity and frequency of blood tests, using smaller collection tubes when compatible with laboratory requirements, and reducing discard volumes can conserve blood without withholding needed assessment.
Anemia treatment and investigation continue after surgery. Decisions about tolerating anemia must account for its severity, rate of change, bleeding, myocardial ischemia, oxygen delivery, and the patient’s clinical condition. Restrictive transfusion trial findings do not establish that extreme anemia is safe.
The paper describes exceptional survival at very low hemoglobin concentrations and specialized rescue approaches. These are not routine treatment thresholds or evidence that severe anemia can reliably be managed without transfusion. Such cases require urgent specialist management within the patient’s documented decisions.
What the Outcome Studies Show
The review draws heavily on observational experience from an established bloodless medicine program. It summarizes an early 294-patient cohort and a larger analysis of 1111 adult bloodless patients, as well as pediatric and cardiac surgery reports. Several comparisons found similar overall morbidity or length of stay, with lower infection rates in some subgroups.
These observations support the feasibility of structured care in experienced centers. They do not prove that avoiding transfusion causes better outcomes. Patient selection, baseline risk, procedure mix, and the ability to decline or postpone high-risk elective operations can influence the comparisons.
The authors also report favorable institutional financial analyses. A combined program return on investment of approximately 7.5-fold included both savings and revenue-related measures; it should not be interpreted as a universally reproducible reduction in direct clinical costs.
Evidence Limits and Disclosures
This is a clinical review, not a new randomized trial comparing complete bloodless and transfusion-inclusive care pathways. Much of the program-outcome evidence is observational and concentrated in one experienced institution. Generalization requires attention to local staffing, infrastructure, and case selection. The religious guidance discrepancy identified above is an additional reason to verify current individual preferences rather than copy the source’s categorical statements.
The work was funded by The New York Community Trust. Frank reports a Haemonetics scientific advisory role; Hensley reports an Octapharma advisory role and author royalties from Wolters Kluwer. The authors disclose AI assistance with tables, references, and editing, with author review and responsibility for the publication.
Original Article
Abib A, Hensley NB, Resar LMS, Frank SM. What to Do When You Can’t Transfuse: Update on Optimizing Outcomes for Jehovah’s Witness Patients. Hematology Reports. 2026;18:69. doi:10.3390/hematolrep18050069.
This independently written educational summary accompanies the unchanged open-access source PDF, published under CC BY 4.0. The editorial update above is based on current official religious guidance and is separate from the source authors’ text. The cover is an AI-generated editorial illustration.
